Roche anticipates USFDA nod for SMA drug Risdiplam by early 2020 Medical Dialogues Bureau26 Nov 2019 9:28 AM ISTRoche, whose drug Risdiplam is seen as a rival for Biogen's Spinraza and Novartis's Zolgensma gene therapy, said the FDA is due to decide by May 24....
Novartis gets USFDA nod for over Rs 13 crore gene therapy Zolgensma Farhat Nasim25 May 2019 10:00 AM ISTThe Food and Drug Administration on Friday approved the treatment, called Zolgensma, for all children under age 2 who are confirmed by a genetic test...